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Abstract: Background and Aims
Endoscopic intervention has emerged as a first-line option for management of
symptomatic pancreatic necrosis, yet endoscopic debridement limited by the lack of
dedicated endoscopic tools intended for this purpose. The objectives of this study were
to design and build a prototype necrosectomy device compatible for use with a flexible
endoscope and capable of selective tissue fragmentation, and to test the prototype in
benchtop and porcine models.
Methods
A novel prototype, named the WAterjet Necrosectomy Device (WAND), was designed
and developed, consisting of a single-use disposable endoscopic waterjet instrument
capable of waterjet selection and independent tip articulation while fitting through a 2.8
mm working channel of a standard adult upper gastrointestinal endoscope. Benchtop,
ex vivo  , and  in vivo  (porcine) testing was performed in the initial stages of
investigation.
Results
The WAND was constructed capable of delivering a continuous waterjet force with a
surface pressure of 0.72 bar at a flow rate of 0.37 L/min. In phase I of testing, the
WAND was able to achieve complete fragmentation of gelatin as a surrogate for
pancreatic necrosis in benchtop testing. In phase II of testing, the WAND was able to
achieve complete fragmentation of freshly explanted human pancreatic necrosis. In
phase III of testing for safety in fresh necropsy swine, use of the WAND resulted in no
significant tissue trauma even when irrigation was applied at closer proximity and at
more extended duration than would be anticipated in clinical use.
Conclusion
The WAND prototype delivers irrigation capable of fragmenting necrotic debris  ex vivo
and also avoiding trauma to healthy non-target tissue. Planning is underway for first-in-
human studies to assess the efficacy and safety of the WAND for endoscopic
pancreatic necrosectomy.
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Background and Aims 
Endoscopic intervention has emerged as a first-line option for management of symptomatic pancreatic 
necrosis, yet endoscopic debridement is limited by the lack of dedicated endoscopic tools intended for 
this purpose.  The objectives of this study were to design and build a prototype necrosectomy device 
compatible for use with a flexible endoscope and capable of selective tissue fragmentation, and to test 
the prototype in benchtop and porcine models. 
Methods 
A novel prototype, named the WAterjet Necrosectomy Device (WAND), was designed and developed, 
consisting of a single-use disposable endoscopic waterjet instrument capable of waterjet selection and 
independent tip articulation while fitting through a 2.8 mm working channel of a standard adult upper 
gastrointestinal endoscope.  Benchtop, ex vivo, and in vivo (porcine) testing was performed in the initial 
stages of investigation.   
Results 
The WAND was constructed capable of delivering a continuous waterjet force with a surface pressure of 
0.72 bar at a flow rate of 0.37 L/minute.  In phase I of testing, the WAND was able to achieve complete 
fragmentation of gelatin as a surrogate for pancreatic necrosis in benchtop testing.  In phase II of 
testing, the WAND was able to achieve complete fragmentation of freshly explanted human pancreatic 
necrosis.  In phase III of testing for safety in fresh necropsy swine, use of the WAND resulted in no 
significant tissue trauma, even when irrigation was applied at closer proximity and at more extended 






































































The WAND prototype delivers irrigation capable of fragmenting necrotic debris ex vivo and also avoiding 
trauma to healthy nontarget tissue.  Planning is underway for first-in-human studies to assess the 
efficacy and safety of the WAND for endoscopic pancreatic necrosectomy. 
 
Introduction 
Acute pancreatitis results in approximately 275,000 hospital admissions and more than $2.5 
billion in health care costs annually [1].  Cases of severe pancreatitis with local adverse events, including 
pancreatic or peripancreatic necrosis, can be associated with significant morbidity and mortality.  Over a 
period of days to weeks after onset of necrotizing pancreatitis, areas of necrosis may evolve to form 
mature collections of walled-off necrosis (WON) which, when symptomatic, require 
intervention/drainage.   
Current practice guidelines suggest that endoscopic intervention is preferred over surgical 
intervention as a first-line approach when drainage of a pancreatic fluid collection (PFC) is indicated [2].    
The initial step in endoscopic drainage consists of EUS-guided access to the collection followed by 
transmural placement of either a lumen-apposing metal stent or double-pigtail plastic stent(s).  The 
resultant fistula tract allows drainage of PFC contents into the GI lumen.   
Although most patients with predominantly liquefied PFC achieve complete resolution with 
stent placement alone, other patients with WON containing solid debris may not achieve complete 
drainage and require further intervention [3].  For patients without complete drainage, a next step often 
consists of transmural retroperitoneal endoscopy.  This can be performed by advancing a flexible 
endoscope first per os then through the previously created fistula and into the retroperitoneal space.  




































































to dislodge from the retroperitoneal cavity without further fragmentation. Options for fragmentation 
include chemical or mechanical debridement, the latter of which is facilitated by off-label use of 
commercially available endoscopic accessories including polypectomy snares, retrieval nets, forceps, 
and biliary stone extraction baskets.   
There are numerous limitations to this current approach: (1) none of the devices are specifically 
designed or intended for this use; (2) as such, these devices are inherently limited in their ability to 
achieve proficient fragmentation of solid necrotic debris; (3) the efficacy and safety of use of these 
devices for this purpose has not been rigorously investigated; (4) use of multiple devices per case results 
in equipment waste and excess cost to the health care system; and (5) complete debridement of 
necrosis is not always achievable in a single endoscopic session, and some patients require multiple 
endoscopic sessions in order to achieve complete clearance of necrosis.   
Development of innovative technologies dedicated for necrosectomy use, capable of 
fragmenting necrotic debris while sparing viable tissue, has been identified as a critical need in the 
endoscopic management of WON [3].  The objectives of this study were to design and build a prototype 
necrosectomy device compatible for use with a flexible endoscope and capable of selective tissue 
fragmentation, and to test the prototype in benchtop and porcine models. 
 
Materials and Methods 
 Design, development, and fabrication of the prototype was performed in the Science and 
Technology of Robotics in Medicine (STORM) Laboratory at Vanderbilt University after Institutional 
Review Board approval. 
The prototype, named the WAterjet Necrosectomy Device (WAND), is a single-use disposable 




































































fitting through a 2.8 mm working channel of a standard adult upper gastrointestinal endoscope (Fig. 1A 
and B).  The WAND is constructed using both “off-the-shelf” and custom 3D-printed parts (Fig. 2).  The 
WAND consists of a handle mechanism, biocompatible polytetrafluoroethylene (PTFE) tubing, and 
device tip.  The waterjet nozzle, device handle, and threaded-filled stopper are manufactured with a 3D 
printer using biocompatible photopolymers (FormLab Dental SG, FormLab, Mass, USA).    The working 
end device tip of the WAND is composed of a 3D-printed nozzle, bending sleeve, and tri-lumen sleeve 
used to separate 2 nitinol wires, which facilitate tip articulation. 
The handle houses a knob where the nitinol wires attach.  The knob rotates on a bearing.  The 
nitinol wires run from the handle, through the length of flexible tubing, to the tip of the WAND.  They 
are separated by a tri-lumen sleeve at the distal end of the WAND to allow for articulation of the tip.  
Rotation of the knob thereby permits articulation of the tip of the WAND over a range of 120 degrees 
while housed in a standard adult upper gastrointestinal endoscope, independent of endoscope tip 
articulation, in order to facilitate precise and accurate targeting of treatment site(s).   
The handle adapter attaches to a Y connector to prevent backflow of water.  Water enters the Y 
connector with a pressurized water line and exits into a 135 cm length of biocompatible PTFE tubing 
coupled with a kink protector and attached with a 3-D printed adapter. 
The WAND is designed to provide a controllable waterjet force capable of safely fragmenting 
necrosis without damage to healthy tissue.  The mechanism of tissue fragmentation is irrigation alone, 
rather than direct contact with the device or mechanical manipulation by the device with necrotic 
tissue.  The water delivery system consists of an ASME-Code pressurized liquid dispensing tank, 
regulator, control valve, and foot pedal (Fig. 3).  The system receives pressurized air from the wall inlet 
in the procedure room.  The air flows into a liquid-dispensing tank that is regulated to have an entry 




































































can then control the pressure in the vessel to a pressure at or below 90 psi.  The air compresses water in 
the vessel, and an electronic depressible foot pedal controls a water release valve, giving the 
endoscopist full control of water irrigation.  When pressing the foot pedal, water will flow out of the 
valve and through tubing to the WAND, with water exiting at the tip of the WAND.  Irrigation is 
sustained as long as the foot pedal is depressed.  Irrigation ceases with release of the foot pedal.  
The WAND is designed to deliver a flow rate up to 0.5 L/minute at a maximum surface pressure 
of 1.3 bar—well below a tissue safety threshold of 3 bar [5-7].  Both the flow rate and force generated 
by the WAND are higher than irrigation volumes and pressures generated by commercially laparoscopic 
irrigation systems used during laparoscopic surgery in the peritoneal and retroperitoneal cavities, yet 
lower than high pressure water jets used for surgical hydrodissection. 
 
Results 
Preclinical testing phase I: Initial benchtop testing used gelatin as a surrogate for pancreatic necrosis to 
assess the ability of the WAND to fragment gelatin and necrosis.  The WAND was tested for its ability to 
fragment different densities of gelatin (Video 1).  The WAND was passed through the instrument 
channel of a gastroscope and positioned at a distance of 2.5 cm from the gelatin.   Irrigation was 
delivered by the WAND, both with and without independent articulation of the WAND tip, with a 
surface pressure of 1 bar at a flow rate of 0.45 L/minute.  The WAND was further tested on gelatin to 
confirm articulation and function in a confined environment, by placing the gelatin in a clear stomach 
phantom (Video 2).  A continuous waterjet force was applied with a surface pressure of 0.72 bar at a 
flow rate of 0.37 L/minute to achieve adequate gelatin fragmentation.  The WAND was then completely 
removed from the endoscope, and fragmented gelatin was successfully aspirated through the empty 




































































successfully and repeatedly re-introduced through the working channel of the endoscope to deliver 
further waterjet irrigation without compromising the function of the WAND.  This would allow for 
multiple cycles of irrigation, fragmentation, and aspiration as would be anticipated in clinical use. 
Preclinical testing phase II: This phase of benchtop testing assessed the WAND’s ability to fragment ex 
vivo freshly explanted pancreatic necrosis from human subjects.  The WAND was passed through the 
instrument channel of a gastroscope and positioned at a distance of 1.5 cm from the necrotic tissue 
(Video 3). Irrigation was delivered by the WAND, both with and without independent articulation of the 
WAND tip, at a surface pressure of 0.72 bar and a flow rate of 0.37 L/minute.  This resulted in successful 
fragmentation of necrotic tissue to remnants less than 2.8 mm in diameter, which is less than the inner 
diameter of the endoscope’s suction channel.  Due to success in aspirating gelatin, given its more 
rigorous and homogeneous composition, aspiration of the brittle necrotic pancreatic tissue after it was 
fragmented to less than 2.8 mm in diameter was not performed.  This phase of testing demonstrated 
the ability of the WAND to fragment pancreatic necrosis as intended for clinical use. 
Preclinical testing phase III: Once the WAND’s effectiveness for ex vivo fragmentation of necrosis was 
demonstrated, preclinical testing was performed in a swine model to evaluate system safety (Video 4).  
In vivo testing was performed using a 40 kg female Yorkshire Landrace cross swine.  This testing was 
performed in fresh necropsy specimens, within 5 minutes of confirmation of death of the swine.  The 
goal of this phase of testing was to demonstrate the absence of tissue trauma caused by the WAND on 
non-target, non-necrotic tissue.  Effects on the pancreas, small intestine, liver, stomach, spleen, and 
aorta were assessed.  We chose to conduct safety testing for “worst case” scenario with irrigation at 
closer proximity and more extended duration than would be anticipated for clinical use.  For each target 
organ, the WAND was positioned 0.5 cm from the porcine organ or vessel, and continuous irrigation was 




































































occur.  There were 5 cases of mild tissue blanching and erythema at surface pressures above 0.72 bar.  
None of the organs or vessels sustained perforation, erosion, or excoriation at any pressures including 
the maximal pressure for the platform.  This phase of testing demonstrated that even when applied 
directly to nontarget tissue at closer proximity and at more extended duration than would be 
anticipated in clinical use, the WAND creates no significant tissue trauma. 
 
Discussion 
The key developmental principle is that the WAND will provide irrigation pressures capable of 
fragmenting nonviable necrotic tissue yet avoiding injury to healthy tissue.  Commercially available 
endoscopic and surgical irrigation devices currently in routine clinical use have provided guidance in the 
intentional design strategy of the WAND in an effort to minimize anticipated risks.  Waterjet dissection is 
currently a technique used for liver and kidney surgery.  Pulsed waterjet dissection in a swine liver 
model has demonstrated that the breaking strength of healthy liver parenchymal tissue is 1.41 mPa 
(14.1bar) and the breaking strength of the hepatic vein is 8.66 MPa (86.6 bar) [4].   Waterjet dissection 
has also become widely used in endoscopic submucosal dissection (ESD), a flexible endoscopic 
procedure for removing neoplastic lesions from the luminal gastrointestinal tract.  A commercially 
available waterjet dissection system for ESD capable of achieving a maximum pressure of 80 bar in the 
endoscopy field was tested in a porcine esophagus model.  According to published data, testing at 30 
bar demonstrated no evidence of tissue dissection.  Testing at 50 bar demonstrated intended and 
desired tissue dissection.  Testing at 70 bar demonstrated perforation of the muscle layer of resection 
bed when waterjet was applied for 1 minute [5]. A different water jet dissector has been tested on the 
stomach walls of pigs with the intention of delivering fluid to the submucosal tissue layer.  This reported 




































































The WAND is designed to deliver a maximum surface pressure of 1.3 bar, which is an order of 
magnitude less than the lower testing limits in the above waterjet dissection studies, which 
demonstrated no evidence of tissue or blood vessel injury as established in above studies.  Avoidance of 
vascular injury is particularly important, as a dreaded potential adverse event of endoscopic pancreatic 
necrosectomy is bleeding caused by damage to the splenic vasculature. 
This 1.3 bar estimate reflects a worst-case scenario that would occur if the WAND tip directly 
contacted tissue during irrigation.  However, the WAND is not intended to directly contact necrotic 
tissue but instead deliver irrigation when positioned 1 to 2 cm from tissue.  This should provide an 
additional margin for safety as prior waterjet dissection data suggests that water pressure drops by 50% 
at 2 mm from the nozzle tip and by 90% at 3.5 mm from the nozzle tip [8].  This worst-case scenario for 
damage to the tissue would occur during maximum tissue irrigation with maximum irrigation exit 
flow.  The 5-mm distance from the tissue was chosen for Phase III testing to ensure maximum tissue 
irrigation, while being very close to the tissue to maintain a focus of the water-jet.  In the case of direct 
or partial tissue contact, the surface pressure would be equal to or less than the perfect irrigation case, 
because the small-diameter nozzle would most likely be obstructed or partially obstructed and therefore 
be unable to operate at maximum flow.  Placement of a clear cap on the endoscope tip could maintain 
distance between the endoscope/WAND tip and tissue thereby preventing direct tissue contact; 
however, we also expect that this modification would constrain independent articulation of the WAND. 
Published, peer-reviewed data regarding use of dedicated devices for endoscopic pancreatic 
necrosectomy are virtually nonexistent.  A European report of use of the EndoRotor, a mechanical 
debridement device, identified no procedure-related adverse events in 2 patients [9].  This small sample 
size is insufficient to determine a current baseline risk of procedure-related adverse events associated 




































































Preclinical testing of the WAND to date is limited in its ability to assess safety for intended use.  
Risk of procedure-related adverse events such as bleeding is inherent to endoscopic pancreatic 
necrosectomy.  Although the WAND has been designed within precise parameters to avoid tissue injury, 
it is unknown whether the rate of adverse events and serious adverse events related to WAND use will 
be increased beyond inherent risks associated with endoscopic pancreatic necrosectomy.  And 
ultimately, the criteria by which endoscopic necrosectomy devices are judged should include 
demonstration of improved outcomes with shorter recovery times and reduced number of procedures. 
It is also possible that further in vivo testing of the WAND will reveal operator challenges or 
technical factors that require device modification.  However, as endoscopic irrigation and irrigation 
control using a foot pedal are customary tasks for an endoscopist, use of the WAND should pose no 
unique critical tasks for the endoscopic user.  Moreover, the device-user interface is intuitive with 
cognitive processing required for device use consisting only of customary endoscopic visual feedback.  
Based on the above testing, our research team has concluded that the WAND is able to deliver 
irrigation capable of (1) fragmenting necrotic debris ex vivo and also (2) avoiding trauma to healthy 
nontarget tissue.  Because there is no available animal model of pancreatic necrosis, the logical next 
step in testing is to assess feasibility and safety of treating pancreatic necrosis in vivo.  Planning is 
underway for first-in-human studies to assess the efficacy and safety of the WAND for endoscopic 
pancreatic necrosectomy. 
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Legends 
Figure 1. A, WAND positioned alongside standard adult upper gastrointestinal endoscope. B, WAND 
housed within standard adult upper gastrointestinal endoscope. 
Figure 2: WAND schematic, exploded with parts labeled. 



































































Acronyms and abbreviations 
EUS (endoscopic ultrasound) 
PFC (pancreatic fluid collection) 
PTFE (polytetrafluoroethylene) 
WAND (WAterjet Necrosecotmy Device) 
WON (walled off necrosis) 









































































Figure 1b: WAND housed within standard adult upper gastrointestinal endoscope  
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